Archive: January 2018

Targeted Therapy for the Adjuvant Treatment of Stage III BRAF-Mutated Melanoma

Georgina Long, PhD, MBBS, FRACP

  H&O  What is considered the standard adjuvant treatment for stage III BRAF-mutated melanoma?  GL  The standard treatment for patients with stage III BRAF-mutated melanoma after […]

Research in Drug Development for Advanced Prostate Cancer

Mario Eisenberger, MD

  H&O  What are the standard approaches for the treatment of advanced prostate cancer? ME There are several treatments approved by the US Food and Drug […]

Checkpoint Inhibition in Lymphoma

Gunjan L. Shah, MD, and Craig H. Moskowitz, MD

  Abstract: Checkpoint inhibition improves surveillance by the immune system and therefore outcomes in some lymphoma subtypes. In this review, we examine the available evidence regarding […]

Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches

Andrew M. Brunner, MD, and David P. Steensma, MD

  Abstract: It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances […]

A Closer Look at Copanlisib

Martin Dreyling, MD

Copanlisib (Aliqopa, Bayer HealthCare) received accelerated approval on September 14, 2017, for the treatment of adults with relapsed follicular lymphoma who have received at least 2 […]

Immunotherapy in Colorectal Cancer 

Dung Thi Le, MD

  H&O  Is colorectal cancer (CRC) a good target for immunotherapy? DL  A subset of patients with CRC have tumors that are found to be deficient […]

Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma

Ranjana H. Advani, MD

  H&O  What is primary mediastinal large B-cell lymphoma? RA Primary mediastinal large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma that is more […]

Hem/Onc News

Devon Schuyler

Axicabtagene, Second CAR T-Cell Therapy, Approved in Lymphoma The US Food and Drug Administration (FDA) approved the T-cell therapy axicabtagene ciloleucel (Yescarta, Kite) on October 18 […]

Letter From the Editor: Another Plenary, More Uncertainty

Brad S. Kahl, MD

  I write this letter 5 days after the 2017 ASH annual meeting. The ASH meeting is always a highlight of the year for hematologists. It is […]

Back to Archive